PURPOSE: The strategy of intracellular antibodies to neutralize the function of target proteins has been widely developed for cancer research. This study used an intrabody against p65 subunit to prevent nuclear factor kappaB (NF-kappaB) transcriptional activity in glioma cells and to inhibit the expression of its target genes involved in the invasion and angiogenesis of human gliomas. EXPERIMENTAL DESIGN: A single-chain fragment of antibody variable region (scFv) against p65 was prepared using phage display technique. We then prepared an anti-p65 intrabody construct (pFv/nu) by cloning the scFv-encoding sequence into the mammalian nuclear-targeting vector, pCMV/myc/nuc. RESULTS: p65 expression in human glioma cells (U251 and] U87) transfected with pFv/nu was significantly decreased. We showed that NF-kappaB nuclear translocation and its DNA binding activity were blocked via intrabody transfection in electrophoretic mobility shift assays and the inhibition of NF-kappaB activity in nucleus resulted in the decreasing expression and bioactivity of matrix metalloproteinase-9, urokinase-type plasminogen activator receptor, urokinase-type plasminogen activator, and vascular endothelial growth factor. The intrabody transfected glioma cells showed a markedly lower level of invasion in Matrigel invasion assay. The capillary-like structure formation of endothelial cells was also repressed by coculture with the intrabody transfected glioma cells or exposure to their conditional medium. Intrabody transfection neither induced apoptosis nor altered cell proliferation in U251 and U87 cells as compared with the control vector pCMV/nu. After the injection of pFv/nu-transfected glioma cells, preestablished tumors were almost completely regressed when compared with mock, pCMV/nu, and pGFP/nu. CONCLUSION: Blocking NF-kappaB activity via the nuclear intrabody expression might be a potential approach for cancer therapy.
PURPOSE: The strategy of intracellular antibodies to neutralize the function of target proteins has been widely developed for cancer research. This study used an intrabody against p65 subunit to prevent nuclear factor kappaB (NF-kappaB) transcriptional activity in glioma cells and to inhibit the expression of its target genes involved in the invasion and angiogenesis of humangliomas. EXPERIMENTAL DESIGN: A single-chain fragment of antibody variable region (scFv) against p65 was prepared using phage display technique. We then prepared an anti-p65 intrabody construct (pFv/nu) by cloning the scFv-encoding sequence into the mammalian nuclear-targeting vector, pCMV/myc/nuc. RESULTS:p65 expression in humanglioma cells (U251 and] U87) transfected with pFv/nu was significantly decreased. We showed that NF-kappaB nuclear translocation and its DNA binding activity were blocked via intrabody transfection in electrophoretic mobility shift assays and the inhibition of NF-kappaB activity in nucleus resulted in the decreasing expression and bioactivity of matrix metalloproteinase-9, urokinase-type plasminogen activator receptor, urokinase-type plasminogen activator, and vascular endothelial growth factor. The intrabody transfected glioma cells showed a markedly lower level of invasion in Matrigel invasion assay. The capillary-like structure formation of endothelial cells was also repressed by coculture with the intrabody transfected glioma cells or exposure to their conditional medium. Intrabody transfection neither induced apoptosis nor altered cell proliferation in U251 and U87 cells as compared with the control vector pCMV/nu. After the injection of pFv/nu-transfected glioma cells, preestablished tumors were almost completely regressed when compared with mock, pCMV/nu, and pGFP/nu. CONCLUSION: Blocking NF-kappaB activity via the nuclear intrabody expression might be a potential approach for cancer therapy.
Authors: M N Mary; C Venot; C Caron de Fromentel; L Debussche; E Conseiller; O Cochet; N Gruel; J L Teillaud; F Schweighoffer; B Tocque; L Bracco Journal: Oncogene Date: 1999-01-14 Impact factor: 9.867
Authors: Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao Journal: J Biol Chem Date: 2005-08-26 Impact factor: 5.157
Authors: Sajani S Lakka; Christopher S Gondi; Niranjan Yanamandra; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: C Caron de Fromentel; N Gruel; C Venot; L Debussche; E Conseiller; C Dureuil; J L Teillaud; B Tocque; L Bracco Journal: Oncogene Date: 1999-01-14 Impact factor: 9.867
Authors: Xueyan Zhao; Travis Laver; Suk W Hong; George B Twitty; Annelies Devos; Marijke Devos; Etty N Benveniste; Susan E Nozell Journal: J Neurooncol Date: 2011-01-30 Impact factor: 4.130
Authors: Christian E Badr; Johanna M Niers; Lee-Ann Tjon-Kon-Fat; David P Noske; Thomas Wurdinger; Bakhos A Tannous Journal: Mol Imaging Date: 2009 Sep-Oct Impact factor: 4.488
Authors: Sreejith P Panicker; Baisakhi Raychaudhuri; Pankaj Sharma; Russell Tipps; Tapati Mazumdar; Asoke K Mal; Juan M Palomo; Michael A Vogelbaum; Saikh Jaharul Haque Journal: Oncotarget Date: 2010-08